Researcher Publications

Wenwei Hu, PhD

Selected Publications

  1. Bond G.L., Hu W. (co-first author), Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., Levine A.J. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. (with commentary) Cell, 119:591-602.
  2. Hu W., Feng Z., Teresky A., Levine A.J. (2007) p53 regulates maternal reproduction through LIF. (with commentary) Nature, 450:721-724.
  3. Kang H., Feng Z., Sun Y., Atwal G., Murphy M., Rebbeck T., Rosenwaks Z., Levine A.J., Hu W. (2009) Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A, 106:9761-9766. (PMC2700980)
  4. Hu W., Chang C., Wu R., Zhang C., Sun Y., Levine A. J. Feng Z. (2010) Negative Regulation of Tumor Suppressor p53 by microRNA miR-504. Molecular Cell., 38:689-699. (PMC2900922)
  5. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A, 107:7455-7460.(PMC2867677)
  6. Feng Z., Liu L., Zhang C., Zheng T., Wang J., Lin M., Zhao Y., Wang X, Levine A. Hu W. (2012) Chronic restraint stress attenuates p53 function and promotes tumorigenesis. PNAS, 109:7013-7018. (PMC3345015)
  7. Zheng T., Wang J., Zhao Y., Zhang C., Lin M., Wang X., Yu H., Liu L., Feng Z., Hu W. (2013) Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nature Communications,4:2996 doi: 10.1038/ncomms3996.(PMC3960723)
    Haupt Y and Haupt S: F1000Prime Recommendation of [Zheng T et al., Nat Commun 2013, 4:2996]. In F1000Prime, 08 Aug 2014; DOI: 10.3410/f.718214290.793498112. F1000Prime.com/718214290#eval793498112
  8. Zhang C., Liu J., Liang Y., Wu R., Zhao Y., Hong X., Lin M., Yu H., Liu L., Levine A., Hu W., Feng Z. (2013) Tumor-Associated Mutant p53 Drives the Warburg Effect. Nature Communications,4:2935 doi: 10.1038/ncomms3935. (PMC3969270)
  9. Yu H., Yue X., Zhao Y., Li X., Wu L., Zhang C., Liu Z., Lin K., Xu-Monette Z., Young K., Liu J., Shen Z., Feng Z., Hu W. (2014) LIF negatively regulates tumor suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nature Communications, 5:5218 doi:10.1038/ncomms6218. (PMC4203416)
  10. Zhao Y., Zhang C., Yue X., Li X., Liu J., Yu H., Belyi V.A., Yang Q., Feng Z., Hu W. (2015) Pontin, a new mutant p53 binding protein, promotes gain of function of mutant p53. Cell Death Differ, 22:1824-1836. (PMC4648328)
  11. Yue X., Zhao Y., Liu J., Zhang C., Yu H., Wang J., Zheng T., Liu L., Li J., Feng Z., Hu W. (2015) BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function. eLIFE, 7554/eLife.08401. (PMC4561369)
  12. Zhang C., Liu J., Zhao Y., Yue X., Zhu Y., Blanco F., Wang X., Bhanot G., Hu W., Feng Z. (2016) Glutaminase 2 is a novel negative regulator of Rac1 and mediates p53 function in suppressing cancer metastasis. eLIFE, 5:e10727. doi: 10.7554/eLife.10727. (PMC4749555)
  13. Zhang C., Liu J., Huang G., Zhao Y., Yue X., Wu H., Li J., Zhu J., Shen Z., Haffty B.G., Hu W., Feng Z. (2016) Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev., 30:1956-1970.
  14. Yue X., Zhao Y., Xu Y., Zheng M., Feng Z., Hu W. (2017) Mutant p53 in cancer: Accumulation, gain-of-function and therapy. J Mol Biol., pii:S0022-2836(17)30163-8.
  15. Yue X., Zhang C., Zhao Y., Liu J., Lin A, Tan V., Drake J., Liu L., Boateng M., Li J., Feng Z., Hu W. (2017) Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. (Editor’s choice) Genes Dev., doi:10.1101/gad.301564.117

Return to member profile

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health